Lung Cancer

Dr. Elizabeth Gore, from the Medical College of Wisconsin, Discusses Hypofractionated Radiotherapy

Jill M. Siegfried, PhD, is an investigator into the role of growth factors and hormones in the development and growth of lung cancer.

An interview with Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, who has dedicated the past 30 years to helping patients with lung cancer.

Dr. Roman Perez-Soler, from Albert Einstein College of Medicine, on the Future of Lung Cancer Therapies

Dr. Chandra Belani from Penn State Hershey Cancer Institute Discusses Driver Mutations in NSCLC

Dr. Roman Perez-Soler, from Montefiore Medical Center, on Treatment Options for NSCLC

Many older patients with stage III lung cancer who received radiation therapy fared no better than those who did not receive radiation therapy.

With the discovery of mutation drivers for NSCLC--including EGFR, KRAS, and EMLA 4-ALK--targeted therapies directed to those mutations are beginning to make a difference.

An aggressive approach to care involving the continuation of chemotherapy within 2 weeks of death does not improve survival in elderly patients with metastatic NSCLC.

Patients with limited and extensive SCLC show incremental gains with different treatment strategies but so far novel agents have failed to make a difference in outcomes.

High-dose radiation was no better than standard-dose radiation given concurrently with chemotherapy in extending survival of patients with advanced unresectable NSCLC.

Patients undergoing lung resection for NSCLC are frequently exposed to a higher dose of radiation than that which has been deemed safe for healthcare workers.

Dr. Chandra Belani, from the Penn State Hershey Cancer Institute, Discusses NSCLC Adjuvant Therapy

Investigators reported that high tumor EGFR expression is a predictive biomarker that defines patients with advanced NSCLC who are most likely to derive a survival benefit from the addition of cetuximab to platinum-based, first-line chemotherapy.

New data show that patients treated for lung cancer at high safety-net burden hospitals undergo curative-intent surgery significantly less often than individuals treated at low safety-net burden facilities.

Martin Steffen, MD, PhD, developed phosphorylation signatures that discriminate between lung tumors and normal lung, and is developing signatures for the prediction of therapy response.

Maintenance therapy with bevacizumab plus pemetrexed achieved a 4-month benefit in progression-free survival (PFS) versus bevacizumab maintenance therapy alone.

A highlight of 3 poster sessions from the 12th International Lung Cancer Congress on August 12, 2011 in Carlsbad, CA.

In the United States, the incidence of lung cancer has increased in those aged >74 years and will likely continue to rise.

A conversation with Denise R. Aberle, MD, on the National Lung Screening Trial (NLST) at the 12th International Lung Cancer Congress.

ASCO endorses a Canadian agency's outlook on ovarian ablation, chemotherapy limits for stage IV lung cancer patients, and supportive care antiemetic therapies.

Dr. Corey Langer from the Abramson Cancer Center Discusses the PARAMOUNT Study

Dr. Rex Yung from Sidney Kimmel Comprehensive Cancer Center Discusses Forming a Multidisciplinary Team

Dr. Gordon Mills from MD Anderson Cancer Center Gives Examples of Unexpected Therapy Responses

Dr. Giorgio Scagliotti from the University of Turin Gives 3 Important Lung Cancer Takeaway Points